Organon & Co | OGN - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Celltrion KRW 12.72B 3.4B 2026-06
Cspc Pharmaceutical CNY 1.87B 95.62M 2025-12
Deva Holding AS TRY 462.26M 48.18M 2023-09
Dianthus Therapeutics USD 12.47M 5.89M 2026-03
Divis Laboratories Ltd INR 3.4B 10M 2025-06
Gilead Sciences USD 1.52B 70M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Kangmei Pharma CNY 253.72M 16.66M 2026-06
Knight Therapeutics CAD 35.45M 4.43M 2025-12
Laboratorios Farma EUR 35.32M 2.75M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Medical Developments International AUD 2.84M 4.19M 2025-12
Merck USD 2.89B 219M 2026-06
Neuren Pharmaceuticals AUD 3.74M 2.5M 2025-12
Novartis USD 3.14B 296M 2026-03
Organigram Holdings CAD 22.01M 14.28M 2026-03
Organon & Co USD 434M 10M 2026-06
Ovoca Bio EUR 617K 15K 2025-12
Pharma Mar EUR 17.12M 1.82M 2026-06
Qiagen NV USD 142.33M 60K 2026-06
Sartorius EUR 216.6M 4.7M 2026-09
Sino Biopharmaceutical CNY 7.54B 2.23B 2025-06
Tilray USD 24.85M 1.7M 2025-09
Zealand Pharma A/S 104M 12.19M 2026-03